Dominick J H McCabe1, Stephen J X Murphy2, Richard Starke3, Paul Harrison4, Martin M Brown5, Paul S Sidhu5, Ian J Mackie3, Marie Scully6, Samuel J Machin7. 1. Department of Neurology, The Adelaide and Meath Hospital incorporating the National Children's Hospital, Trinity College, Dublin, Ireland; Stroke Service, The Adelaide and Meath Hospital, incorporating the National Children's Hospital, Trinity College, Dublin, Ireland; Stroke Research Group, UCL Institute of Neurology, The National Hospital for Neurology & Neurosurgery, UK; Department of Clinical Neurosciences, Royal Free Campus, UCL Institute of Neurology, The National Hospital for Neurology & Neurosurgery, UK; Haemostasis Research Unit, University College, London, UK. Electronic address: dominick.mccabe@amnch.ie. 2. Department of Neurology, The Adelaide and Meath Hospital incorporating the National Children's Hospital, Trinity College, Dublin, Ireland; Stroke Service, The Adelaide and Meath Hospital, incorporating the National Children's Hospital, Trinity College, Dublin, Ireland. 3. Haemostasis Research Unit, University College, London, UK. 4. School of Immunity and Infection, University of Birmingham Medical School, UK. 5. Stroke Research Group, UCL Institute of Neurology, The National Hospital for Neurology & Neurosurgery, UK. 6. Dept. of Haematology, University College, London, UK. 7. Haemostasis Research Unit, University College, London, UK; Dept. of Haematology, University College, London, UK.
Abstract
BACKGROUND: Reduced ADAMTS13 activity is seen in thrombotic thrombocytopenic purpura (TTP), and may lead to accumulation of prothrombotic ultra-large von Willebrand factor (ULVWF) multimers in vivo. ADAMTS13 activity and its relationship with VWF antigen (VWF:Ag) levels and platelet function in 'non-TTP related' TIA or ischaemic stroke has not been comprehensively studied. METHODS: In this prospective pilot observational analytical case-control study, ADAMTS13 activity and VWF:Ag levels were quantified in platelet poor plasma in 53 patients in the early phase (≤ 4 weeks) and 34 of these patients in the late phase (≥ 3 months) after TIA or ischaemic stroke on aspirin. Data were compared with those from 22 controls not on aspirin. The impact of ADAMTS13 on platelet function in whole blood was quantified by measuring Collagen-ADP (C-ADP) and Collagen-Epinephrine closure times on a platelet function analyser (PFA-100(®)). RESULTS: Median ADAMTS13 activity was significantly reduced in the early phase (71.96% vs. 95.5%, P <0.01) but not in the late phase after TIA or stroke compared with controls (86.3% vs. 95.5%, P=0.19). There was a significant inverse relationship between ADAMTS13 activity and VWF:Ag levels in the early phase (r=-0.31; P=0.024), but not in the late phase after TIA or stroke (P=0.74). There was a positive correlation between ADAMTS13 activity and C-ADP closure times in early phase patients only, likely mediated via VWF:Ag levels. DISCUSSION: ADAMTS13 activity is reduced and VWF:Ag expression is increased within 4 weeks of TIA or ischaemic stroke onset, and can promote enhanced platelet adhesion and aggregation in response to stimulation with collagen and ADP via VWF-mediated pathways. These data improve our understanding of the dynamic haemostatic and thrombotic profiles of ischaemic cerebrovascular disease (CVD) patients, and are important in view of the potential future role that ADAMTS13 may have to play as an anti-thrombotic agent in CVD.
BACKGROUND: Reduced ADAMTS13 activity is seen in thrombotic thrombocytopenic purpura (TTP), and may lead to accumulation of prothrombotic ultra-large von Willebrand factor (ULVWF) multimers in vivo. ADAMTS13 activity and its relationship with VWF antigen (VWF:Ag) levels and platelet function in 'non-TTP related' TIA or ischaemic stroke has not been comprehensively studied. METHODS: In this prospective pilot observational analytical case-control study, ADAMTS13 activity and VWF:Ag levels were quantified in platelet poor plasma in 53 patients in the early phase (≤ 4 weeks) and 34 of these patients in the late phase (≥ 3 months) after TIA or ischaemic stroke on aspirin. Data were compared with those from 22 controls not on aspirin. The impact of ADAMTS13 on platelet function in whole blood was quantified by measuring Collagen-ADP (C-ADP) and Collagen-Epinephrine closure times on a platelet function analyser (PFA-100(®)). RESULTS: Median ADAMTS13 activity was significantly reduced in the early phase (71.96% vs. 95.5%, P <0.01) but not in the late phase after TIA or stroke compared with controls (86.3% vs. 95.5%, P=0.19). There was a significant inverse relationship between ADAMTS13 activity and VWF:Ag levels in the early phase (r=-0.31; P=0.024), but not in the late phase after TIA or stroke (P=0.74). There was a positive correlation between ADAMTS13 activity and C-ADP closure times in early phase patients only, likely mediated via VWF:Ag levels. DISCUSSION: ADAMTS13 activity is reduced and VWF:Ag expression is increased within 4 weeks of TIA or ischaemic stroke onset, and can promote enhanced platelet adhesion and aggregation in response to stimulation with collagen and ADP via VWF-mediated pathways. These data improve our understanding of the dynamic haemostatic and thrombotic profiles of ischaemic cerebrovascular disease (CVD) patients, and are important in view of the potential future role that ADAMTS13 may have to play as an anti-thrombotic agent in CVD.
Authors: Alejandro Bustamante; MingMing Ning; Teresa García-Berrocoso; Anna Penalba; Cristina Boada; Alba Simats; Jorge Pagola; Marc Ribó; Carlos Molina; Eng Lo; Joan Montaner Journal: Neurology Date: 2018-02-14 Impact factor: 9.910
Authors: David Green; Lu Tian; Philip Greenland; Kiang Liu; Melina Kibbe; Russell Tracy; Sanjiv Shah; John T Wilkins; Mark D Huffman; Yihua Liao; Donald Lloyd Jones; Mary M McDermott Journal: Clin Appl Thromb Hemost Date: 2016-06-17 Impact factor: 2.389
Authors: Frederik Denorme; Peter Kraft; Inge Pareyn; Christiane Drechsler; Hans Deckmyn; Karen Vanhoorelbeke; Christoph Kleinschnitz; Simon F De Meyer Journal: PLoS One Date: 2017-06-07 Impact factor: 3.240
Authors: Nina Buchtele; Michael Schwameis; James C Gilbert; Christian Schörgenhofer; Bernd Jilma Journal: Thromb Haemost Date: 2018-05-30 Impact factor: 5.249
Authors: Susan M Graham; Robin M Nance; Junmei Chen; Jennie Le; Dominic W Chung; Mark M Wurfel; David L Tirschwell; Joseph R Zunt; Christina M Marra; Emily L Ho; Andrew Huffer; Felicia C Chow; Jeffrey N Martin; Alice S Ryan; Heidi M Crane; José A López; W Conrad Liles Journal: Open Forum Infect Dis Date: 2021-10-21 Impact factor: 4.423
Authors: Stephen J X Murphy; Soon Tjin Lim; Fionnuala Hickey; Justin A Kinsella; Deirdre R Smith; Sean Tierney; Bridget Egan; T Martin Feeley; Sinéad M Murphy; D Rónán Collins; Tara Coughlan; Desmond O'Neill; Joseph A Harbison; Prakash Madhavan; Sean M O'Neill; Mary-Paula Colgan; James S O'Donnell; Jamie M O'Sullivan; George Hamilton; Dominick J H McCabe Journal: Thromb Haemost Date: 2020-09-15 Impact factor: 5.249